Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer

Published:2017-02-06 Issue:6 Volume:83 Page:1216-1226
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Brown Kathryn¹,Comisar Craig²,Witjes Han²,Maringwa John²,de Greef Rik²,Vishwanathan Karthick³,Cantarini Mireille⁴,Cox Eugène²

Affiliation:

1. UCB; Slough UK

2. Quantitative Solutions, a Certara company; Breda The Netherlands

3. AstraZeneca; Waltham USA

4. AstraZeneca, Alderley Park; UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13223/fullpdf

Reference11 articles.

1. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands;Southan;Nucl Acids Res,2016

2. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes;Alexander;Br J Pharmacol,2015

3. AZD9291, an irreversible EGFR TKI, overcomes T790 M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014

4. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Jänne;N Engl J Med,2015

5. AZD9291 in treatment-naive EGFRm advanced NSCLC: AURA first-line cohort. Presented in mini oral session, WCLC Denver 6-9 September 2015;Ramalingam;J Thorac Oncol,2015

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of 40 mg osimertinib administered every other day for non‐small cell lung cancer harboring an epidermal growth factor receptor mutation: A single‐center retrospective cohort study;Thoracic Cancer;2024-01-27

2. A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma;Therapeutic Drug Monitoring;2024-01-24

3. Integrated PBPK-EO Modeling of Osimertinib: Predicting Pharmacokinetics, Intracranial EGFR Engagement, and Optimal Dosing Strategies in Clinical Settings;2024-01-12

4. Intervention effect of Lycium barbarum polysaccharide on lead-induced kidney injury mice and its mechanism: A study based on the PI3K/Akt/mTOR signaling pathway;Journal of Ethnopharmacology;2024-01

5. CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients;Frontiers in Pharmacology;2023-11-06